GANX — Gain Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $21.84m
- $9.69m
- $0.06m
Annual cashflow statement for Gain Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.19 | -3.58 | -13.9 | -17.6 | -22.3 |
| Depreciation | |||||
| Non-Cash Items | 0.01 | 0.09 | 1.89 | 1.32 | 2.88 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.312 | 0.237 | -0.385 | 1.51 | 0.442 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -1.87 | -3.24 | -12.4 | -14.7 | -18.9 |
| Capital Expenditures | -0.014 | -0.021 | -0.094 | -0.119 | -0.015 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -14.7 | 10.2 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.014 | -0.021 | -0.094 | -14.8 | 10.2 |
| Financing Cash Flow Items | 0 | -0.471 | -0.853 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.75 | 10.5 | 41.8 | -0.079 | 12.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.097 | 7.19 | 29.4 | -29.6 | 4.49 |